Synthekine has entered a clinical trial partnership and supply agreement with Merck (MSD) to investigate STK-012 in combination with Keytruda (pembrolizumab) and chemotherapy in patients with ...
Synthekine Inc., an engineered cytokine therapeutics company, today announced that it has entered into a clinical trial collaboration and supply agreement with Merck (known as MSD outside of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results